DNER and cardiovascular disorder: RVX-208 was the earliest known BD2-selective BET inhibitor to induce a more specific expression profile compared with the gene expression altered in response to JQ1.134 The limited range of genes impacted by RVX-208 diminishes its efficacy as an antitumor medication, but because of its anti-inflammatory effects, it is well tolerated as a treatment for cardiovascular disease and type 2 diabetes.135–138